eluting stents" in the end of this sentence. 2. Page 9, line 52. Stenotic coronary lesion of > 50% diameter stenosis is defined as suitable for stent implantation in this trial. Why this protocol uses 50% stenosis as the criterion of significant stenosis rather than conventional 70%? Does this study use a central core angiographic laboratory to perform the quantitative coronary angiography? 3. Page 12, line 33. The trial applies permute-block randomization with a block size of 8. Does the trial apply stratified randomization using center (or hospital) as a stratum? 4. Page 14, how to deal with patients who are assigned to the 3-month DAPT arm but actually use DAPT for longer than 3 months? 5. Page 15, line 38. "Using the proportional-hazards model, clinical outcomes will be compared between the stent types and DAPT strategies, possibly after controlling for relevant covariates." It is not necessary for a RCT to control for relevant covariates if randomization has been applied and well conducted. 6. Page 22, this study is also supported by Biotronik Korea and B. Braun Korea. Why this is not construed to be competing interests among the authors?
VERSION 1 -AUTHOR RESPONSE
# Reviewer: 1 Reviewer Name: Gen-Min Lin Institution and Country: Hualien-Armed Forces General Hospital, Taiwan Reviewer"s comment: Dr. Kim and colleagues will design a RCT, 2x2 factorial, non-inferior trial to compare TLF and DAPT between Orsiro and CX-ISAR. In general, the study is well designed and the protocol is well-written. I have only one major concern that in the 2017 ACC annual meeting, the ABSORB-3 showed more MACE in the BVS arm at 2-year follow-up that warrants the safety in use of bioabsorbable stent for CAD patients, particularly those with small vessel diameter <2.5mm. Since those with small vessel diameter will not be excluded in the inclusion, whether 3-month DAPT treatment may be at risk for late TLF in these patients is unknown. In my opinion, the authors may need to provide more evidence to show the safety of 3-month DAPT using Orsiro and CX-ISAR in those with small vessel intervention.
Response to reviewer #1 (Dr. Gen-Min Lin, Hualien-Armed Forces General Hospital, Taiwan). Thank you for your careful review. As you pointed out, patients with small-vessel intervention are at a higher risk of experiencing ischemic adverse events and are generally recommended for prolonged DAPT. In fact, the intervention for small-vessel diameter (<3mm) is an item of the DAPT score and is included in the model to predict the occurrence of the future ischemic adverse events.1 Recent guidelines recommend that the duration of DAPT maintenance be determined based on the patient's lesional and procedural characteristics.2 For this reason, it is not surprising that patients with smallvessel intervention may have a poor outcome if they maintain DAPT for a shorter period of 3-or 6-months rather than the conventional 1-year DAPT. However, the clinical efficacy of 3-month DAPT in small-vessel intervention has been demonstrated in several previous studies. In the RESET study that validated the clinical usefulness and safety of the 3-month DAPT, subgroup analysis was performed by dividing the diameter of the intervening vessels by 3 mm.3 Interestingly, even if the diameter of the vessel was small, maintaining DAPT for only 3 months did not adversely affect the clinical outcome (p-for-interaction 0.105). And the OPTIMIZE study, which was another randomized clinical trial using the 3-month DAPT regimen, showed no significant interaction with vessel size and duration of the DAPT maintenance (p-for-interaction 0.43).4 Both studies used the Endeavor and Resolute stents (zotarolimus-eluting stents), which are no longer used in clinical practice. Both the Orsiro or Coroflex-ISAR stents to be used in this HOST-IDEA trial have ultrathin strut thickness and minimized or absent polymer burden. As the stent platform is improved, we do not expect to find a significant difference in clinical outcomes even when the 3-month DAPT regimen is implemented. In fact, both the Bioscience trial, a previous study using the Orsiro stent, and the ISAR-TEST 5 study, a trial using the previous version of the Coroflex-ISAR stent, showed that about one-third to half of the patients enrolled had a vessel size less than 2.75 mm.5 6 In these two studies, the clinical outcomes of the Orsiro and the prototype of the Coroflex-ISAR stents were not different from those of conventional everolimus-or zotarolimus-eluting stents even in small-vessel diameter. However, since these studies have applied the DAPT maintenance period of at least 6 months, there is no data to date on the 3-month DAPT maintenance. Based on these considerations, we also planned this study to prove that the combination of the 3-month DAPT regimen and the Orsiro or the Coroflex-ISAR stents might be clinically useful and safe for small-vessel intervention. In order to reflect the comments of the reviewer and supplement the shortcomings, the following sentences were added to the last paragraph of the discussion: In addition, this study may also provide meaningful data on the clinical usefulness of the 3-month DAPT regimen for small-vessel intervention. In fact, the intervention for small-vessel diameter (<3mm) is an item of the DAPT score and is included in the model to predict the occurrence of the future ischemic adverse events. In this regard, the recent guideline has advised that long-term DAPT maintenance should be considered for small-vessel intervention. There is, of course, data that contradict this recommendation. Some previous studies such as the RESET and OPTIMIZE trials have shown that the 3-month DAPT regimen is clinically useful and safe even in small-vessel intervention. However, these studies used the Endeavor and Resolute zotarolimus-eluting stents, which are no longer used in the current clinical practice. To date, detailed data on the effect of the combination of the 3-month DAPT regimen and the new stent platforms on small-vessel intervention are very scarce. In this context, even if the 3-month DAPT regimen were used for the Orsiro or the CX-ISAR stents, we expect that excellent clinical outcome can also be achieved in small-vessel intervention.
